



The Prescribing of MEBO Ointment in a Public Hospital in Alkharj

**Nehad J. Ahmed ^{a*}, Ahmed H. Almutairi ^b, Faris A. Alotaibi ^c
and Menshawy A. Menshawy ^d**

^a *Clinical Pharmacy Department, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.*

^b *Specialized Clinics for Security Forces, Hafar Al Batin, Saudi Arabia.*

^c *Specialized Clinics for Security Forces, Jeddah, Saudi Arabia.*

^d *Department of Medicinal Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i59B34397

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/80142>

Original Research Article

Received 08 October 2021

Accepted 17 December 2021

Published 18 December 2021

ABSTRACT

Aim: The present study aimed to describe the prescribing of moist exposed burn ointment (MEBO) in Alkharj.

Methodology: This is a retrospective study that includes reviewing the electronic prescriptions that included MEBO among the patients who received medications from the outpatient department in a public hospital in Alkharj.

Results: More than 61% of the patients who received MEBO ointment were female patients and about 61.98% of them received MEBO ointment for 1 week. Most of the prescribers were residents (76.86%). More than 46% of the prescriptions were prescribed by emergency department, about 24% were prescribed by plastic surgery department.

Conclusion: The use of MEBO ointment in the outpatient setting in Alkharj was uncommon. Further studies are needed to explore the pattern of using burn treating ointments such as MEBO ointment in the outpatient setting and in other settings.

Keywords: Burn ointment; MEBO; outpatient; use.

1. INTRODUCTION

Burn injury is a worldwide problem that equally concerns developed, under-developed, and developing countries. Even after the advances in burns' care, the selection of the most suitable dressing material for burns is still elusive [1]. The use of silver sulfadiazine for treating burns has remained the standard management of partial-thickness burn wounds for more than four decades but it causes several adverse effects such as local skin reaction, painful dressing changes, hypersensitivity reactions and occasionally self-limiting leucopenia [1]. One of the main alternative agents for treating the burn is moist exposed burn ointment (MEBO) [1].

MEBO is an oil-based herbal ointment, purported to be efficacious in managing burn wounds and more frequently used in the Middle East and in Asia [2]. It is a Chinese burn ointment with a USA patented formulation, has been reported to promote chronic ischemic and neurogenic ulcer healing in patients [3]. MEBO is natural in origin and contains beta-sitosterol, *Scutellaria baicalensis*, *Phellodendron amurense*, *Coptis chinensis*, Beeswax, *Pheretima aspergillum*, and sesame oil [4].

Beta-sitosterol has been shown to have anti-inflammatory effects, [5] and berberine has antimicrobial effects [5]. Numerous studies have confirmed the rapid, healing of MEBO in acute and chronic wounds [6,7].

Using MEBO could cause some side-effects that may occur from all constituting ingredients of Mebo Burn Ointment such as skin rashes, diarrhea, and hair loss [8]. Li et al stated that that MEBO is an effective and safe therapy for treating pressure ulcers in Chinese patients but larger studies conducted over a longer treatment period are still needed [9].

There is a lack in studies about the frequency of using MEBO and other medications that is used for the treatment of burn wounds. So, the present study aimed to describe the prescribing of Mebo cream in Alkharj.

2. METHODOLOGY

This was a retrospective study that included reviewing the electronic prescriptions that

included MEBO ointment among the patients who received medications from the outpatient department in a public hospital in Alkharj. The inclusion criteria included outpatient prescriptions that contained MEBO ointment during the study period. The outpatient prescriptions that didn't contain MEBO ointment and the inpatient prescriptions were excluded from the study.

The collected data included patients' personal data, the number of prescriptions that included MEBO ointment and that were prescribed during different months of the study, duration of MEBO ointment use, the level of prescribers who prescribed MEBO ointment, and the departments that prescribed MEBO ointment.

The data were collected from electronic medical records as an Excel file and the data were represented as frequencies and after that each frequency divided by the total numbers, and then multiplying the result by 100% to find the percentages.

3. RESULTS AND DISCUSSION

MEBO ointment was prescribed for 121 patients during the study period. More than 61% of the patients were female patients and the age of 37.19% of them was between 20 and 29 years. Table 1 shows the personal data of the patients.

Table 2 shows the number of prescriptions that included MEBO ointment and that were prescribed during different months of the study. More than 10% of the prescriptions were dispensed in May and 10.74% were dispensed in December.

Table 3 shows the duration of MEBO ointment use. About 61.98% of the patients received MEBO ointment for 1 week.

Table 4 shows the level of prescribers who prescribed MEBO ointment. Most of the prescribers were residents (76.86%).

Table 5 shows the departments that prescribed MEBO ointment. More than 46% of the prescriptions were prescribed by emergency department, about 24% were prescribed by plastic surgery department, and 18.18% of the prescriptions were prescribed by obstetrics & gynecology department.

Table 1. The personal data of the patients

Variable	Category	Number	Percentage
Gender	Female	75	61.98
	Male	46	38.02
Age	Less than 10	20	16.53
	10-19	11	9.09
	20-29	45	37.19
	30-39	15	12.40
	40-49	7	5.78
	50-59	15	12.40
	60-69	3	2.48
Nationality	More than 69	5	4.13
	Saudi	82	67.77
	Non- Saudi	39	32.23

Table 2. The number of prescriptions that included MEBO ointment

Month	Number	Percentage
January	9	7.44
February	6	4.95
March	11	9.09
April	9	7.44
May	13	10.74
June	12	9.92
July	9	7.44
August	12	9.92
September	11	9.09
October	8	6.61
November	8	6.61
December	13	10.74

Table 3. The duration of MEBO ointment use

Duration	Number	Percentage
3 Days	1	0.83
5 Days	8	6.61
1 Week	75	61.98
10 Days	1	0.83
2 Weeks	27	22.31
3 Weeks	9	7.44

Table 4. The level of prescribers

Prescribers Level	Number	Percentage
Specialist	11	9.09
Resident	93	76.86
Consultant	17	14.05

Table 5. The departments that prescribed MEBO ointment

Department	Number	Percentage
Emergency	56	46.28
Internal Medicine	2	1.65
General Surgery	4	3.30
Nephrology	5	4.13
Obstetrics & Gynecology	22	18.18
Plastic Surgery	29	23.97
E.N.T	1	0.83
Dermatology	2	1.65

The use of MEBO ointment was uncommon in the outpatient setting in Alkharj. In contrast to this result, Mabvuure stated that MEBO is prescribed frequently to manage burn wounds, mainly in Asia and the Middle East [2]. Hong-Bo et al stated that MEBO is one of the commonly used medicines for skin ulcers [10]. Jewo et al. stated that MEBO is an efficacious and an appropriate alternative to conventional silver-based topical treatments for managing partial-thickness burn wounds and that concerns about the toxicity of purified chemicals will continue to make people turn to complementary and alternative medicines such as MEBO [11].

Although MEBO was prescribed for only 60 patients during the first 6 months of the year in a public hospital in Alkharj, silver sulfadiazine was prescribed to only 30 patients in 12 months [12]. More than half of the MEBO prescriptions in the present study were prescribed by emergency department or by plastic surgery department. This is rational because the patients who have burns are usually treated by these departments.

Most of the prescriptions in the present study were prescribed by residents and this is rational because MEBO is an over the counter drug that is generally safe. Moreover, most of the patients received MEBO ointment for 1 or 2 weeks. This is also rational as the superficial and partial-thickness burns usually heal within 2 weeks unless complications such as infection or chronic diseases occur [13,14].

4. CONCLUSION

The use of MEBO ointment in the outpatient setting in Alkharj was uncommon. Further studies are needed to explore the pattern of using burn treating ointments such as MEBO ointment in the outpatient setting and in other settings.

CONSENT

It is not applicable.

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author (s).

ACKNOWLEDGEMENT

"This Publication was supported by the Deanship of Scientific Research at Prince Sattam bin Abdulaziz University"

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Saraf S. Moist exposed burn ointment role of alternative therapy in the management of partial-thickness burns. *Indian J Dermatol Venereol Leprol.* 2010;76:415-417.
2. Mabvuure NT, Brewer CF, Gervin K, Duffy S. The use of moist exposed burn ointment (MEBO) for the treatment of burn wounds a systematic review. *J Plast Surg Hand Surg.* 2020;54(6):337-343.
3. Tang Q, Han S, Feng J, Di J, Qin W, Fu J, et al. Moist exposed burn ointment promotes cutaneous excisional wound healing in rats involving VEGF and BFGF. *Mol Med Rep.* 2014;9:1277-1282.
4. Hirsch T, Ashkar W, Schumacher O, Steintraesser L, Ingianni G, Cedidi C. Moist exposed burn ointment (MEBO) in partial thickness burns. *Eur J Med Res.* 2008;13:505-10.
5. Gupta MB, Nath R, Srivastava N, Shanker K, Kishor K, Bhargava KP. Anti-inflammatory and antipyretic activities of beta-sitosterol. *Planta Med.* 1980;39:157-163.
6. Atiyeh BS, Ioannovich J, Al-Amm CA, El-Musa KA, Dham R. Improving scar quality a prospective clinical study. *Aesthetic Plast Surg.* 2002;26:470-6.
7. Atiyeh BS, Al-Amm CA, Nasser A A. Improved healing of split-thickness skin graft donor sites. *J Applied Research.* 2002;2:114-21.
8. Tabletwise. Mebo burn ointment; 2021. Available:<https://www.tabletwise.net/malaysia/mebo-burn-ointment>.
9. Li W, Ma Y, Yang Q, Pan Y, Meng Q. Moist exposed burn ointment for treating pressure ulcers a multicenter randomized controlled trial. *Medicine.* 2017;96(29):e7582.
10. Zhan HB, Sun QQ, Yan L, Cai J. Clinical study of MEBO combined with jinhuang powder for diabetic foot with infection. *Evid Based Complement Alternat Med.* 2021; 2021:5531988.
11. Jewo PI, Fadeyibi IO, Babalola OS, Saalu LC, Benebo AS, Izegbu MC, et al. A comparative study of the wound healing properties of moist exposed burn ointment

- (MEBO) and silver sulphadiazine. Ann Burns Fire Disasters. 2009;22(2): 79–82.
12. Ahmed NJ. The outpatient prescribing of silver sulfadiazine in Al-Kharj. J Pharm Res Int. 2021;33(48A):195-199.
 13. Kao CC, Garner WL. Acute burns. Plast Reconstr Surg. 2000;101:2482-2493.
 14. Hirsch T, Ashkar W, Schumacher O, Steinstraesser L, Ingianni G, Cedidi C. Moist Exposed Burn Ointment (MEBO) in partial thickness burns - a randomized, comparative open mono-center study on the efficacy of dermaheal (MEBO) ointment on thermal 2nd degree burns compared to conventional therapy. Eur J Med Res. 2008;13(11):505-10.

© 2021 Ahmed et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/80142>